As of Nov 27
| +0.02 / +1.41%|
The 1 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +247.22% increase from the last price of 1.44.
The current consensus among 1 polled investment analysts is to Buy stock in Rosetta Genomics Ltd. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.